The utility of LECT2 as a biomarker was validated first in a mouse liver tumor model where exon-3 mutation in β-catenin gene and ensuing β-catenin activation is implicated in HCC pathogenesis [14], [15]. This evidence concerns the gene LECT2 and hepatocellular carcinoma.